StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research note released on Tuesday. The firm issued a sell rating on the stock.
A number of other analysts also recently weighed in on the company. Maxim Group decreased their price objective on Moleculin Biotech from $45.00 to $20.00 and set a buy rating for the company in a report on Tuesday, March 26th. Roth Mkm reiterated a buy rating and set a $40.00 price target on shares of Moleculin Biotech in a report on Friday, April 12th.
View Our Latest Analysis on MBRX
Moleculin Biotech Stock Performance
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last released its earnings results on Friday, May 10th. The company reported ($2.02) earnings per share for the quarter, topping the consensus estimate of ($3.59) by $1.57. As a group, research analysts predict that Moleculin Biotech will post -8.79 EPS for the current fiscal year.
Institutional Investors Weigh In On Moleculin Biotech
A hedge fund recently bought a new stake in Moleculin Biotech stock. Armistice Capital LLC purchased a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 3,207,417 shares of the company’s stock, valued at approximately $2,753,000. Armistice Capital LLC owned 9.60% of Moleculin Biotech at the end of the most recent reporting period. Institutional investors own 15.52% of the company’s stock.
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Featured Stories
- Five stocks we like better than Moleculin Biotech
- 3 REITs to Buy and Hold for the Long Term
- Is This Telehealth Stock a Buy After the Recent Pullback?
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Safeguard Against Credit Card Risks with This Top Financial Stock
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Streaming Titan’s Stock Ready to Hit All-Time Highs This Year
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.